NCT05113459Unknown2 期
A Phase Ⅱ Clinical Study of Disitamab Vedotin Combined With Anti-PD-1 Antibody and Capecitabine in Neoadjuvant Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With Moderate and High Expression of HER2
Guoxin Li0 个研究点目标入组 40 人开始时间: 2021年12月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 主要终点
- pathologic Complete Response, PCR
研究概览
简要总结
This trial is a multi-center, open, single-arm, superior phase II clinical study.
详细描述
The study included 40 patients with gastric cancer or gastroesophageal junction adenocarcinoma with clinical stage T3-4aN+M0; and confirmed after HER2 IHC results Patients with medium and high expression of HER2 (defined as: IHC 2+ 3+); the neoadjuvant treatment plan is: disitamab vedotin + PD-1 + capecitabine; the main goal of the study is to explore The effectiveness of disitamab vedotin combined with PD-1 monoclonal antibody and capecitabine in the neoadjuvant treatment of locally advanced gastric or gastroesophageal junction adenocarcinoma, and ultimately provide a basis for the update of treatment decisions for locally advanced gastric or gastroesophageal junction adenocarcinoma Proof of medical evidence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent form;
- •Age 18-75 years old (including 18 years old and 75 years old);
- •Expected survival period ≥ 12 weeks;
- •ECOG physical fitness score 0 or 1 point;
- •Patients with gastric cancer or gastroesophageal junction adenocarcinoma (Siewert type I-III) confirmed by histology and/or cytology, clinical stage T3-4aN+M0 (determined by the 8th edition of the AJCC staging system);
- •Use pre-treatment endoscopic biopsy samples for HER2 detection in the local laboratory: HER2 high expression confirmed after IHC results (defined as: IHC 2+ 3+);
- •Sufficient organ function:
- •Bone marrow function: hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×10 9/L; white blood cell count ≥3.0×10 9/L; platelet ≥100×10 9/L; Liver function: serum total bilirubin ≤1.5 times the upper limit of normal (ULN); when there is no liver metastasis, alanine aminotransferase (ALT), aspartate aminotransferase (AST and alkaline phosphatase (ALP) ≤2.5 × ULN; Renal function: blood creatinine ≤ 1.5×ULN, or creatinine clearance rate (CrCl) ≥ 60 mL/min calculated by Cockcroft-Gault formula method; Heart function: NYHA classification <3; left ventricular ejection fraction ≥50%;
- •For female subjects: women of childbearing age agree to use a medically approved contraceptive method (such as intrauterine device, contraceptives, or contraceptives) during the study treatment period and within 6 months after the end of the study treatment period for the test group participants Set), the blood pregnancy test must be negative within 7 days before the study administration (surgical sterilization or subjects aged ≥60 years can choose not to have a blood pregnancy test), and must be non-lactating; for male subjects: should For surgical sterilization, or agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period of the experimental group subjects;
- •Must voluntarily join this study and sign an informed consent form.
排除标准
- •Stage IV (metastatic) or unresectable gastric cancer or gastroesophageal junction adenocarcinoma (GEJ) as determined by the investigator;
- •Past systemic treatment for gastric cancer;
- •There is a history of malignant tumors in the 5 years before screening (except for gastric cancer), except for malignant tumors with negligible risk of metastasis or death (for example, 5-year OS rate> 90%), such as cervical carcinoma in situ after appropriate treatment , Non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ or stage I uterine cancer;
- •Severe cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage and cerebral infarction (except for lacunar infarcts that are asymptomatic and do not require treatment);
- •There are other lung diseases that require treatment or are serious, including but not limited to active tuberculosis, interstitial lung disease, etc.;
- •Are suffering from an active infection that requires systemic treatment;
- •There are active autoimmune diseases that require systemic treatment in the past 2 years (such as corticosteroids or immunosuppressive drugs, etc.), and related alternative treatments (such as thyroxine, insulin, or the physiological effects of adrenal or pituitary insufficiency) are allowed Corticosteroid replacement therapy);
- •Major surgery other than diagnosis was received within 4 weeks before the start of study treatment, or major surgery is expected to be required during the study period
- •Serious infections that occurred within 4 weeks before the start of the study treatment, including but not limited to hospitalization due to complications of infection, bacteremia, or severe pneumonia
- •Treat with therapeutic antibiotics within 2 weeks (intravenous antibiotics) or 5 days (oral antibiotics) before starting the study treatment
- •Patients who receive prophylactic antibiotics (for example, to prevent urinary tract infections or prevent exacerbations of chronic obstructive pulmonary disease) are eligible to participate in the study.
- •Have previously received allogeneic stem cell or solid organ transplantation;
- •Any other diseases, metabolic dysfunction, physical examination results or clinical laboratory results that lead to the prohibition of the use of experimental drugs, affect the interpretation of the results, put the patient at a high risk of treatment complications;
- •All treatments using live attenuated vaccines within 4 weeks before the start of the study treatment, or expected to be vaccinated during PD-1 treatment or within 5 months after the last PD-1 administration;
- •Have a clear history or current history of neurological or mental disorders, including epilepsy or dementia;
- •HIV test results are positive; patients with active hepatitis B or C (HBsAg positive and HBV DNA titers higher than the upper limit of normal when HBsAg is positive; HCVAb positive and HCV RNA titers higher than the upper limit of normal when HBsAg is positive);
- •There are factors that significantly affect the absorption of oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction;
- •In patients who choose to receive capecitabine, it is required to use the antiviral drug solivudine (antiviral drug) or chemical structure analogs, such as brivudine. These drugs are not allowed to be used within 4 weeks before the start of study treatment including capecitabine;
- •Known to have hypersensitivity or delayed allergic reactions to certain components of RC48-ADC or similar drugs;
- •Those who are allergic to PD-1;
- •It is estimated that the compliance of the patient to participate in this clinical study is sufficient or the researcher thinks that there are other subjects who are not suitable to participate in this study.
研究组 & 干预措施
disitamab vedotin + PD-1+Capecitabine
Experimental
disitamab vedotin：2.5mg/kg,iv,d1,q2w ,6cycle PD-1: 200mg,iv,d1,q2w，6cycle Capecitabine：1000mg/m2 ,po, bid,d1-14,q3w, 4cycle
干预措施: Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy (Drug)
结局指标
主要结局
pathologic Complete Response, PCR
时间窗: 3 months-6 months
After completion of neoadjuvant systemic therapy (NAST), hematoxylin and eosin (H\&E) assessments were performed on the completely resected gastric cancer or gastroesophageal junction adenocarcinoma sample and all sampled regional lymph nodes. No evidence of residual active tumor cells was found (currently YpT0N0 in the 8th edition of the AJCC staging system)
次要结局
- Overall survival , OS(1-5 years)
- Relapse-free survival time , RFS(1-5 years)
- Objective response rate, ORR(3 months-6 months)
- Major pathologic response, MPR(3 months-6 months)
- R0 resection rate(3 months -6 months)
研究者
Guoxin Li
Chief Physician
Nanfang Hospital, Southern Medical University
相似试验
招募中
2 期
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric CarcinomaNCT06730373Qilu Hospital of Shandong University110
招募中
2 期
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableHer2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNCT05495724Tianjin Medical University Second Hospital176
尚未招募
2 期
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerHER2-positive Gastric CancerNCT06492317The First Affiliated Hospital of Zhengzhou University20
招募中
2 期
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerCastration-resistant Prostate CancerNCT06227156RemeGen Co., Ltd.40
招募中
2 期
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct AdenocarcinomaBile Duct Adenocarcinoma Non-ResectableHER2 Gene MutationNCT06383533Zhejiang Cancer Hospital28